Status | Study |
Recruiting |
Study Name: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Condition: Choroidal Neovascularization Date: 2016-08-21 Interventions: Drug: 0.5mg intravitreal ranibizumab Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerla |
Recruiting |
Study Name: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization Condition: Idiopathic Choroidal Neovascularization Date: 2016-07-27 Interventions: Drug: conbercept 0.05ml conbercept Other Name: conbe |
Withdrawn |
Study Name: Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID). Condition: Choroidal Neovascularization in Angioid Streaks Date: 2015-10-07 Interventions: Drug: Aflibercept The patients are followed on a monthly basis until 52 weeks. Intravitreal injections o |
Recruiting |
Study Name: AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Condition: Macular Degeneration, Choroidal Neovascularization Date: 2015-06-12 Interventions: Drug: RG7716 Participants will |
Recruiting |
Study Name: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Condition: Type 3 Choroidal Neovascularization Date: 2014-12-10 Interventions: Drug: Aflibercept |
Recruiting |
Study Name: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization Condition: Choroidal Neovascularization Date: 2014-10-06 Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) Administration by intravitreal injection |
Recruiting |
Study Name: Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients Condition: Idiopathic Choroidal Neovascularization Date: 2014-10-02 Interventions: Drug: aflibercept The patients are followed on a monthly basis until 52 weeks. Intravitreal injections o |
Completed |
Study Name: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Condition: Choroidal Neovascularization Secondary to Pathologic Myopia Date: 2014-01-09 Interventions: Drug: Ranibizumab All patients will receive a single initial intravitreal injection of ranibizumab 0.5 m |
Completed |
Study Name: Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Condition: Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Date: 2013-08-12 Interventions: Drug: Ranibizumab 0.5mg 0.5 mg |
Completed |
Study Name: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Condition: Choroidal Neovascularization (CNV) Date: 2013-04-23 Interventions: Drug: Ranibizumab Ranibizumab |